Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
LSTALisata Therapeutics(LSTA) Newsfilter·2024-04-23 19:30

Lisata Therapeutics与Qilu Pharmaceutical合作 - Lisata Therapeutics与Qilu Pharmaceutical宣布在中国进行的第二期试验中，首位患者接受了LSTA1治疗[1] - Qilu正在进行一项120名患者的随机、双盲、多中心、安慰剂对照试验，评估LSTA1与标准治疗联合治疗胰腺癌的有效性[2] - LSTA1是一种正在研发的药物，旨在激活一种新的摄取途径，使抗癌药物更有效地渗透实体肿瘤[4]